CAMBRIDGE, Mass., May 20, 2024 Foghorn Therapeutics Inc. today announced the pricing of a registered direct offering of 12,743,039 shares of its common stock at a price of $5.51 per share,.
ProQR Announces First Quarter 2024 Operating and Financial Results marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer™ RNA Editing Program Targeting NTCP for Cholestatic Diseases tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Dose escalation in FHD-286 combination trial in AML continues to progress with clinical data expected in the second half of 2024; potential to be a first-in-class oral broad-based differentiation.
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 23, 2024 ProQR Therapeutics NV. , a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™.